This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           November 19, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

FDA approves bevacizumab for recurrent ovarian cancer
Medscape (Free login required)
The U.S. Food and Drug Administration (FDA) has approved bevacizumab for use in combination with chemotherapy in the treatment of women with platinum-resistant, recurrent ovarian cancer. This marks the first FDA-approved treatment option for women with this type of ovarian cancer in more than 15 years.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Annual Meeting early bird registration now open
Early bird registration for SGO’s 2015 Annual Meeting on Women’s Cancer is open until Monday, Jan. 26, 2015. Member/non-member fees and online registration are available on the SGO website. SGO Chicago-based members and staff have extended a special video invitation to all SGO members to “See You in Chicago” March 28-31.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Virus drug combo helps to fight ovarian cancer
Science World Report
Researchers have discovered a new treatment that combines a viral infection and chemotherapy to target cancer cells in women with advanced or recurrent ovarian carcinoma. Now, findings published in the journal Clinical Cancer Research show that combining tumor growth can be reduced when combined with a chemotherapy drug known as doxorubicin, which fights recurrent cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


Salpingectomy associated with reduced ovarian cancer risk
Ob.Gyn.News
Surgical removal of the fallopian tubes could be a viable option for reducing the risk of ovarian cancer in high-risk women, a speaker said at the biennial meeting of the International Gynecologic Cancer Society. Dr. Henrik Falconer, head of gynecologic oncology at the Karolinska Institute, Stockholm, said there is an emerging hypothesis that ovarian cancer arises primarily in the fallopian tubes, not in the ovaries, although this is difficult to prove.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV


When cervical cancer is common, HPV vaccination usually isn't, study finds
Los Angeles Times
Rates of cervical cancer vary substantially from state to state, and health experts hoped that the HPV vaccine would help even them out. But new research shows that hasn’t happened – at least not so far. As of 2012, some of the states with the highest incidence of cervical cancer also did the worst job of vaccinating girls against human papillomavirus, the virus that can lead to cervical cancer, according to a study presented at a health disparities conference organized by the American Assn. for Cancer Research.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Probable/possible carcinogenic HPV types are biologically active
HealthDay News via Healthcare Professionals Network
Molecular evidence indicates that eight probable/possible high-risk human papillomavirus (pHR-HPV) types are biologically active, according to a study published in the December issue of The Journal of Pathology. Gordana Halec, from the German Cancer Research Center in Heidelberg, and colleagues analyzed the biological activity of pHR-HPV in direct comparison to HR-HPV types. Fifty-five formalin-fixed paraffin-embedded cervical cancer (CxCa) tissues harboring single pHR-HPV infections and 266 tissues harboring single HR-HPV were selected from a worldwide, retrospective, cross-sectional study. Two genotyping methods were used to verify single HPV infection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


No recurrence of cervical cancer seen with simple trachelectomy
The Oncology Report
Simple trachelectomy can achieve fertility-sparing outcomes similar to those obtained from radical trachelectomy in women with early-stage cervical cancer without any increased risk of recurrence, according to a poster presented at the biennial meeting of the International Gynecologic Cancer Society. A retrospective cohort study of 25 patients who underwent a simple vaginal trachelectomy to remove the cervix after a diagnosis of cervical cancer found that 6 of the 10 patients who declared an intention to conceive were successful in doing so.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Novel radiotherapy techniques expand options for breast cancer patients
OncLive
Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing. One such noteworthy development in the last several years has been the popularization of breast conservation surgery and the advancement of radiation options that go hand in hand with it.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


GENETICS


First genetic-based tool to detect circulating cancer cells in blood
Medical Xpress
Scientists have demonstrated a simple tool that can detect live cancer cells in the bloodstream, potentially long before the cells could settle somewhere in the body and form a dangerous tumor. The technology is the first genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


RESEARCH


Study: Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer
Clinical Cancer Research
The results were similar when restricted to 3,202 patients with high-grade serous tumors, and to ovarian cancer specific mortality. Conclusions: BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and, in BRCA1 carriers is eventually reversed. This may have important implications for therapy of both primary and relapsed disease and for analysis of long-term survival in clinical trials of new agents, particularly those that are effective in BRCA1/2 mutation carriers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRACTICE


Why no one can design a better speculum
The Atlantic
Few women enjoy pelvic exams: the crinkly paper dress, the awkward questions, the stirrups, the vague fear that can comes with doctors visits of any kind (what if they find something abnormal, something bad, something cancerous?). But perhaps no piece of the pelvic exam is as reviled as the vaginal speculum — the cold, clicking, duck-billed apparatus that lifts and separates the vaginal walls so a near-stranger can peer inside.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Nov. 12, 2014
Nov. 5, 2014
Oct. 29, 2014
Oct. 15, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063